

FOI – 1417

24th May 2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs :

• Aubagio (teriflunomide)	49
• Avonex (interferon beta-1a)	49
• Betaferon (interferon beta-1b)	<5
• Brabio (glatiramer acetate)	0
• Copaxone (glatiramer acetate)	35
• Extavia (beta interferon-1b)	0
• Gilenya (fingolimod)	25
• Lemtrada (alemtuzumab)	29
• Kesimpta (ofatumumab)	<5
• Mavenclad (cladribine)	<5
• Mayzent (siponimod)	<5
• Ocrevus (ocrelizumab)	76
• Plegridy (peginterferon beta-1a)	13

Part 2:

• Ponvory (ponesimod)	0
• Rebif (beta interferon-1a)	21
• Tecfidera (dimethyl fumarate)	222
• Tysabri (natalizumab)	<5
• Tysabri (natalizumab) pre-filled syringes ONLY	38
• Vumerity (diroximel fumarate)	0
• Zeposia (ozanimod)	0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the ‘world at large’ and is published on the

Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

It would also be very helpful if you could advise how many hospital patients (inpatients or outpatients) currently have a diagnosis for the following conditions:

- Multiple sclerosis (any type) **Approx 1100 cannot differentiate between types**
- Relapsing remitting multiple sclerosis (RRMS)
- Primary progressive multiple sclerosis (PPMS)

Part 3:

- Secondary progressive multiple sclerosis (SPMS)

Please see attached spreadsheet for the number of inpatient finished consultant episodes with a primary or secondary diagnosis of Multiple Sclerosis. Out-patient episodes are not coded and a manual search of a large number of patient records would have to be undertaken. The cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information it would exceed the £450 limit and is therefore cost prohibitive.